2,4-pyrimidinediamine compounds and their uses
AssigneeRigel Pharmaceuticals, Inc.
InventorsRajinder Singh, Ankush Argade, Jeffrey Clough, Holger Keim, Someasekhar Bhamidipati, Catherine Sylvain, Hui Li
Life of this patent
Estimating the term…
Abstract
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Claims21
A process for preparing a compound of formula (I):
- comprising contacting a compound of formula (II):
- or a salt or N-oxide thereof, with 2,4-dichloro-5-fluoropyrimidine under conditions to provide for the compound of formula (I);
- wherein
- Y is selected from the group consisting of O, S, SO, SO2, S(O)NR36, NH, and NR35;
- Z is selected from the group consisting of O, S, SO, SO2, S(O)NR36, NH, and NR35;
- each R35, independently of the others, is selected from the group consisting of hydrogen and
- R8, or, alternatively, two R35 bonded to the same carbon atom are taken together to form an oxo (═O) group;
- each R36, independently, is selected from the group consisting of hydrogen and R8;
- each R8, independently, is selected from the group consisting of Ra, Rb, Ra substituted with one or more of the same or different Ra or Rb, —ORa substituted with one or more of the same or different Ra or Rb, —B(ORa)2, —B(NRcRc)2, —(CH2)m—Rb, —(CHRa)m—Rb, —O—(CH2)m—Rb, —S—(CH2)m—Rb, —O—CHRaRb, —O—CRa(Rb)2, —O—(CHRa)m—Rb, —O—(CH2)m—CH[(CH2)mRb]Rb, —S—(CHRa)m—Rb, —C(O)NH—(CH2)m—Rb, —C(O)NH—(CHRa)m—Rb, —O—(CH2)m—C(O)NH—(CH2)m—Rb, —S—(CH2)m—C(O)NH—(CH2)m—Rb, —O—(CHRa)m—C(O)NH—(CHRa)m—Rb, —S—(CHRa)m—C(O)NH—(CHRa)m—Rb, —NH—(CH2)m—Rb, —NH—(CHRa)m—Rb, —NRCH2)mRb]2, —NH—C(O)—NH—(CH2)m—Rb, —NH—C(O)—(CH2)m—CHRbRb and —NH—(CH2)m—C(O)—NH—(CH2)m—Rb;
- each Ra, independently, is selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, (C6-C16) arylalkyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
- each Rb, independently, is selected from the group consisting of —ORd, (C1-C3) haloalkyloxy, —SRd, —NRcRc, halogen, —CF3, —CN, —NC, —OCN, —SCN, —NO, —NO2, —N3, —S(O)Rd, —S(O)2Rd, —S(O)2ORd, —S(O)NRcRc, —S(O)2NRcRc, —OS(O)Rd, —OS(O)2Rd, —OS(O)2ORd, —OS(O)2NRcRc, —C(O)Rd, —C(O)ORd, —C(O)NRcRc, —C(NH)NRcRc, —C(NRa)NRcRc, —C(NOH)Ra, —C(NOH)NRcRc, —OC(O)Rd, —OC(O)ORd, —OC(O)NRcRc, —OC(NH)NRcRc, —OC(NRa)NRcRc, —[NHC(O)]nRd, —[NRaC(O)]nRd, —[NHC(O)]nORd, —[NRaC(O)]nORd, —[NHC(O)]nNRcRc, —[NRaC(O)n]NRcRc, —[NHC(NH)]nNRcRc and —[NRaC(NRa)]nNRcRc;
- each Rc, independently, is Ra, or alternatively, two Rc, each taken together with the nitrogen atom to which it is bonded, form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different Ra or Rb groups;
- each Rd independently is Ra;
- each m independently is an integer from 1 to 3;
- and
- each n independently is an integer from 0 to 3.
Dependencies are inferred from the claim text.